Evidence map›Paper›PMID 36286260›Full record

ArticleThe New England journal of medicine2022

Protection against Omicron from Vaccination and Previous Infection in a Prison System.

Elizabeth T Chin, David Leidner, Lauren Lamson, Kimberley Lucas, David M Studdert, Jeremy D Goldhaber-Fiebert, Jason R Andrews, Joshua A Salomon

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Elizabeth T ChinFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.ORCID 0000-0001-5774-4236
David LeidnerFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.
Lauren LamsonFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.
Kimberley LucasFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.
David M StuddertFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.
Jeremy D Goldhaber-FiebertFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.
Jason R AndrewsFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.ORCID 0000-0002-5967-251X
Joshua A SalomonFrom the Departments of Biomedical Data Science (E.T.C.) and Health Policy (L.L., D.M.S., J.D.G.-F., J.A.S.) and the Division of Infectious Diseases and Geographic Medicine (J.R.A.), Stanford University School of Medicine, and Stanford Law School (D.M.S.), Stanford, the California Department of Corrections and Rehabilitation, Sacramento (D.L.), and California Correctional Health Care Services, Elk Grove (K.L.) - all in California.ORCID 0000-0003-3929-5515
Stanford University · USFranciscan Health · US

Funding

Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
CDC HHS NU38OT000297-02NIDA NIH HHS R37 DA015612NIDA NIH HHS R37-DA15612
6 · The paper itself

Abstract

backgroundInformation regarding the protection conferred by vaccination and previous infection against infection with the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is limited.

methodsWe evaluated the protection conferred by mRNA vaccines and previous infection against infection with the omicron variant in two high-risk populations: residents and staff in the California state prison system. We used a retrospective cohort design to analyze the risk of infection during the omicron wave using data collected from December 24, 2021, through April 14, 2022. Weighted Cox models were used to compare the effectiveness (measured as 1 minus the hazard ratio) of vaccination and previous infection across combinations of vaccination history (stratified according to the number of mRNA doses received) and infection history (none or infection before or during the period of B.1.617.2 [delta]-variant predominance). A secondary analysis used a rolling matched-cohort design to evaluate the effectiveness of three vaccine doses as compared with two doses.

resultsAmong 59,794 residents and 16,572 staff, the estimated effectiveness of previous infection against omicron infection among unvaccinated persons who had been infected before or during the period of delta predominance ranged from 16.3% (95% confidence interval [CI], 8.1 to 23.7) to 48.9% (95% CI, 41.6 to 55.3). Depending on previous infection status, the estimated effectiveness of vaccination (relative to being unvaccinated and without previous documented infection) ranged from 18.6% (95% CI, 7.7 to 28.1) to 83.2% (95% CI, 77.7 to 87.4) with two vaccine doses and from 40.9% (95% CI, 31.9 to 48.7) to 87.9% (95% CI, 76.0 to 93.9) with three vaccine doses. Incremental effectiveness estimates of a third (booster) dose (relative to two doses) ranged from 25.0% (95% CI, 16.6 to 32.5) to 57.9% (95% CI, 48.4 to 65.7) among persons who either had not had previous documented infection or had been infected before the period of delta predominance.

conclusionsOur findings in two high-risk populations suggest that mRNA vaccination and previous infection were effective against omicron infection, with lower estimates among those infected before the period of delta predominance. Three vaccine doses offered significantly more protection than two doses, including among previously infected persons.

Indexed as

COVID-19COVID-19 VaccinesPrisonsVaccinationCaliforniaHumansImmunization, SecondaryPolicePrisonersReinfectionRetrospective StudiesSARS-CoV-2Vaccine EfficacyCOVID-19 Vaccines

Identifiers

PMID36286260
PMCPMC9634863
OpenAlexW4307343122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.